Physician profile
Johnathan D Mize
NPI 1679505465
$14,804.79
in general payments reported to CMS, 2019-2025
44 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,024 · 2020: $1,228 · 2021: $1,879 · 2022: $2,059 · 2023: $2,304 · 2024: $2,013 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,615.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,979.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $2,136.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $2,007.10 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,014.31 | 2019-2025 | |
| Abbvie INC. | $980.19 | 2021-2025 | |
| Amgen INC. | $978.18 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $831.91 | 2019-2024 | Jardiance, Synjardy, Trijardy Xr |
| Lilly USA, LLC | $548.76 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Novartis Pharmaceuticals Corporation | $514.06 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.26 | 2020-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $355.24 | 2019-2021 | |
| Esperion Therapeutics, INC. | $310.59 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $308.14 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Corcept Therapeutics | $148.18 | 2024 | Korlym |
| Astellas Pharma US INC | $120.74 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Mize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.